Spero Therapeutics Hires Cristina Larkin as Chief Commercial Officer

Spero Therapeutics Hires Cristina Larkin as Chief Commercial Officer

April 05, 2016

CAMBRIDGE, Mass, April 5, 2016 – Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that Ankit Mahadevia, President and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 10:20 a.m. ET in New York, NY.

About Spero
Spero is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections and is located in Cambridge, Massachusetts. The company’s pipeline of anti-infective agents is one of the most unique in the industry. Spero is pioneering an entirely new therapeutic platform called the Potentiator; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include Gram-negative pathogens. Spero’s DHFR program is exploring the expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens. The investors in Spero include Atlas Ventures, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group, Osage Partners and The Partners Innovation Fund. For more information, please visit www.sperotherapeutics.com

MEDIA CONTACT:
Spectrum Science Communications:
Maia Arnold, PhD
Senior Scientific Executive
202-955-6222 x2506
marnold@spectrumscience.com

INVESTOR CONTACT:
Stern Investor Relations
Beth DelGiacco, Vice President
212-362-1200
Beth@sternir.com